12

Here’s Why a Cardiologist Took a Second Look At Cannabis

www.sgim.org

www.sgim.org

The Society for General Internal Medicine is an organization of Internal Medicine specialists. They publish a traditional medical journal on a monthly basis and they also periodically publish a newsletter titled The Forum. The Forum discusses a different medical topic, in depth, in each issue. The current issue, March 2016, deals entirely with cannabis. This demonstrates the continued and growing interest of traditional physicians in the medical benefits of cannabis.

Our good friend, Dr. Joe D Goldstrich of Zelda Therapeutics, was asked to contribute an article for this issue of the forum on his experience with medical cannabis. Dr. Joe has been practicing medicine for longer than most of you reading this have been alive (over 50 years).

Read below to discover why after 50 years of practicing medicine a cardiologist decided to take a second look at cannabis as medicine…

A Cardiologist Becomes a Cannabinologist

By: Joe D. Goldstrich, MD, FACC

It was 2012, and I had recently turned 74. I had retired from a satisfying career in preventive cardiology, nutrition, integrative medicine, and clinical lipidology. I was bored and depressed. Still fit and able to think clearly, what was I to do with the rest of my life? All my medical licenses except for California and Missouri were now inactive.

Joe D. Goldstrich, MD, FACC

Joe D. Goldstrich, MD, FACC

I saw an ad for a job in Pomona, California, to work in a medical marijuana clinic. I wasn’t exactly sure what this entailed, so I investigated and found that it was a job providing recommendations for the use of medical marijuana, which had been legal in California since 1996. I thought this might provide relief from my doldrums and malaise, so I signed on.

I saw about 25 patients a day— mostly young men with purported low back pain who were looking for a legal way to smoke marijuana. There were a few interesting patients who told me how cannabis relieved their migraine headaches,1 Crohn’s disease,2 low back pain,3 glaucoma,4 multiple sclerosis spasms,5 and insomnia.6 One woman was looking for cannabis to relieve the side effects of chemotherapy.7

Some, but not all the applicants, brought medical records documenting their diagnosis.

I lasted six days because providing the recommendation without supporting medical records, a requirement of the California medical board, was too stressful for me. I was fortunate enough to find other interesting work as the medical director of a nutritional supplement company. I remembered those interesting medical marijuana patients and continued to follow the medical marijuana job opportunities in California.

In late 2013, I saw an ad for a medical marijuana clinic in Oakland, California. This clinic was part of a group of clinics belonging to Jean Talleyrand, MD, founder and president of MediCann. Dr. Talleyrand advertised that his clinics were “highly professional, ethical …founded and run by physicians.” I flew to California and spent three days seeing patients with Dr. Talleyrand. I was impressed with his professionalism and extensive experience with MediCann in providing medical marijuana recommendations to more than 300,000 California patients. I signed on again, and over the next nine months interviewed close to 3,000 patients seeking a recommendation for medical cannabis.8

During this period of time, my list of medical conditions for which patients found cannabis useful grew to include attention deficit hyperactivity disorder,9 asthma,10 anxiety,11 seizures,12 depression,13 post-traumatic stress disorder,14 erectile dysfunction,15 and cancer.16 (Regarding cancer, cannabis not only provided relief from chemotherapy but also appeared to treat the tumor—more on this later.)

It gradually dawned on me that while I had been providing the legal mechanism for patients to use medical cannabis to treat their medical condition, I had little to no firsthand knowledge or experience in guiding patients on using cannabis to treat their conditions. It was then that I decided to become a bona fide cannabinologist.

More to learn.

In 2014, I joined the Society of Cannabis Clinicians,17 a professional society devoted to the exploration and investigation of medical and scientific applications of cannabis medicine. Shortly after joining, Mara Gordon, a layperson who had been making cannabis oil for medical purposes, spoke to the society. She had been advising patients on how to use cannabis medicinally for several years.

In September 2014, while attending a continuing medical education program on medical cannabis in Denver, Colorado, I heard Mara present again. Mara was supplying medical cannabis oil to really sick people – people with cancer, people who were deemed incurable after exhausting traditional medical therapy. She had supplied medical cannabis to hundreds of patients over several years and had more experience in advising patients on the use of medical cannabis than anyone else that I had encountered. I asked Mara to teach me what she knew about the use of medical cannabis – to let me learn from her experience. This was not an easy thing for a physician to do, but I was willing to do whatever was needed to gain this knowledge. That was the spring of 2015.

Most of the patients I have consulted on have had cancer. I have followed the tumor markers and radiologic scans. Some tumors have shrunk and even disappeared, some have stopped growing, and some have continued to grow unabated. Cannabis is not an oncologic panacea, but I’ve seen enough success to remain cautiously optimistic about the role of cannabis in the treatment of cancer.

In a nutshell, here are some of the most important things I have learned about the use of cannabis in the treatment of cancer:

  1. Cannabis may work synergistically with chemotherapy18 and radiation.19
  2. Cannabis may induce autophagy and subsequent apoptosis resulting in programmed cancer cell death.20
  3. Tumor ID-1 gene expression facilitates cancer cell growth, survival, and metastases.21
  4. Cannabidiol (CBD), a non- psychoactive cannabinoid, expresses antitumor activity22 in part through inhibition and down regulation of ID-1 expression.23

How can this information be used to formulate a therapeutic protocol to treat patients?

Many people envision the medical cannabis patient as someone who sits around the house smoking a joint all day long. That’s not usually the case. Smoking might be an effective way to prevent a migraine headache or deal with a flare-up of chronic pain, but for most chronic diseases a concentrated form of cannabis is necessary and is best delivered by the transmucosal route. Accurate laboratory testing of the cannabis material is mandatory. This testing would include not only the percentage of the cannabinoids present in the material (i.e. THC, CBD) but also the absence of pesticides and toxic solvents and the presence of the full cannabinoid and terpene profile so as to take advantage ofthe entourage effect.24

Once the percentage of the cannabinoids are known, a prescription can be formulated in terms of milligrams of THC and/or CBD. Typical prescriptions for cancer patients will contain from 50 to 300 mg per day of THC and, depending on the status of the ID-1 gene for their particular tumor, from 50 to 300 mg per day of CBD. Specific strains, over and above their THC and CBD con- tent, are chosen for their secondary effects (i.e. wakefulness, appetite stimulation, sleep).

Most patients are seeking to avoid the psychoactivity associated with THC, and for that reason it is of paramount importance to start with extremely low doses (i.e. 1 to 5 mg) of THC and build up slowly, taking advantage of the known tolerance that develops with continued THC use. CBD, having little psychoactivity, can usually be advanced more quickly.

That’s what I have learned so far. My experience convinces me that cannabis should be removed from its schedule 1 status so placebo controlled, double-blind studies can be carried out. Only then will we realize the full potential of this remark- able medicine.

References

1. Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been. Headache 2015;
55(6):885-916.
2. Schicho R, Storr M. Cannabis finds its way into treatment of Crohn’s disease. Pharmacology 2014; 93(1-2):1-3.
3. Eisenberg E, Ogintz M, Almog S. The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. J Pain Palliat Care Pharmacother 2014; 28(3):216-25.
4. Sun X, Xu CS, Chadha N, Chen A, Liu J. Marijuana for glaucoma: a recipe for disaster or treatment? Yale J Biol Med 2015; 88(3):265-9.
5. Pryce G, Baker D. Endocannabinoids in multiple sclerosis and amyotrophic lateral sclerosis. Handb Exp Pharmacol 2015; 231:213-31.
6. Belendiuk KA, Babson KA, Vandrey R, Bonn-Miller MO. Cannabis species and cannabinoid concentration preference among sleep- disturbed medicinal cannabis users. Addict Behav 2015; 50:178-81.
7. Smith LA, Azariah F, Lavender VTC, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 2015; 11:CD009464.
8. Thompson M. The mysterious history of “marijuana.” NPR.org. Available at: http://www.npr.org/ sections/codeswitch/2013/07/14/201981025/the-mysterious- history-of-marijuana (accessed on January 2, 2016).
9. Hadland SE, Knight JR, Harris SK. Medical marijuana: review of the science and implications for developmental-behavioral pediatric practice. J Dev Behav Pediatr 2015; 36(2):115-23.
10. Tashkin DP, Shapiro BJ, Lee YE, Harper CE. Effects of smoked marijuana in experimentally induced asthma. Am Rev Respir Dis 1975; 112(3):377-86.
11. Korem N, Zer-Aviv TM, Ganon Elazar E, Abush H, Akirav I. Targeting the endocannabinoid system to treat anxiety-related disorders. J Basic Clin Physiol Pharmacol 2015.
12. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2015; 4422(15):379-8.
13. Hillard CJ, Liu Q. Endocannabinoid signaling in the etiology and treatment of major depressive illness. Curr Pharm Des 2014; 20(23):3795-811.
14. Betthauser K, Pilz J, Vollmer LE. Use and effects of cannabinoids in military veterans with posttraumatic stress disorder. Am J Health Syst Pharm 2015; 72(15):1279-84.
15. Chauhan NS, Sharma V, Dixit VK, Thakur M. A review on plants used for improvement of sexual performance and virility. BioMed Res Int 2014; 2014:868062.
16. Giuliano M. Cannabinoid- associated cell death mechanisms in tumor models
(Review). Int J Oncol, May 2012.
17. Society of Cannabis Clinicians. http://cannabisclinicians.org/ (accessed on January 2, 2016).
18. Torres S, Lorente M, Rodríguez- Fornés F, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 2011; 10(1):90-103.
19. Scott KA, Dalgleish AG, Liu WM. The combination of cannabidiol and ∆9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol Cancer Ther 2014; 13(12):2955-67.
20. Salazar M, Carracedo A, Salanueva IJ, et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 2009; 119(5):1359-72.
21. Ling M-T, Wang X, Zhang X, Wong Y-C. The multiple roles of Id-1 in cancer progression. Differ Res Biol Divers 2006; 74(9-10):481-7.
22. McAllister SD, Soroceanu L, Desprez P-Y. The antitumor activity of plant-derived non-psychoactive cannabinoids. J Neuroimmune Pharmacol 2015; 10(2):255-67.
23. McAllister SD, Murase R, Christian RT, et al. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat 2011; 129(1):37-47.
24. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7): 1344-64.

About the Author
Joe D. Goldstrich, MD, FACC

Joe D. Goldstrich, MD, FACC

Dr. Joe Goldstrich graduated from the University of Texas Southwestern Medical School in 1964. He completed fellowships in diabetes, metabolism, and cardiology and became board certified in internal medicine, cardiology and clinical lipidology.​ He has had a distinguished clinical career in preventive cardiology and nutrition, working as the National Director of Education and Community Programs for the American Heart Association, Medical Director at the Pritikin Longevity Center and Medical Director of ProCaps Laboratories, where he designed nutritional supplements based on published scientific studies. He has authored four books on diet, nutrition and preventive cardiology. He began practicing cannabis medicine in 2012. He has evaluated over 3500 patients using cannabis as a fundamental medicine in the management of their medical conditions. His most recent work has focused on the use of cannabis in the clinical management of cancer. He serves on the Board of Directors of the Society of Cannabis Clinicians and is their liaison to the California Medical Board. He lives in Iowa and California. Dr. Goldstrich is medical director at Zelda Therapeutics.

Read More